CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 35 enrolled
Drug / intervention
Cephalexin +1 moredrug
Likely dose
Cephalexin 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06127160
NCT06127160Phase 4Completed
CompareCT.gov

Personalized Antibiotic Treatment in the Emergency Department: Panther Trial

Brett A Faine·interventional·Posted Nov 13, 2023·Updated Sep 12, 2025

In Brief

A Phase 4 clinical trial evaluating Cephalexin and Cephalexin or placebo for Pyelonephritis Acute. Completed, enrolled 35 participants across 2 sites.

Detailed Summary

This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale multi-center randomized controlled trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPyelonephritis Acute
CountriesUnited States
CollaboratorsUniversity of California, Los Angeles

Timeline

Phase 4CompletedFinished
202420252026
First PostedNov 13, 2023
Enrollment StartJun 4, 2024
Primary CompletionAug 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.6 years ago

Interventions

Cephalexindrug

Cephalexin 1000 mg by mouth 3 times daily for 10 days

Cephalexin or placebodrug

Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.